Wellcome Open Research (Mar 2022)
An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams [version 2; peer review: 2 approved]
- Shadrack Mutua,
- Brian Bartilol,
- Shaban J. Mwangi,
- Debra Riako,
- Lydia Nyamako,
- Bonface M. Gichuki,
- Henry Karanja,
- Angela Karani,
- John N. Gitonga,
- Daisy Mugo,
- Brian Tawa,
- Wilson Gumbi,
- Wesley Cheruiyot,
- Metrine Tendwa,
- John K. Nyambu,
- Yiakon Sein,
- Thani Suleiman Thani,
- Shem O. Patta,
- Benson Kitole,
- Eric K. Maitha,
- Barke S. Muslih,
- Mohamed S. Mwakinangu,
- Philip Bejon,
- Benjamin Tsofa,
- Joyce U. Nyiro,
- John Ochieng Otieno,
- Leonard Ndwiga,
- Patience Kiyuka,
- Johnstone Makale,
- Kevin Wamae,
- Victor Osoti,
- John Mwita Morobe,
- Calleb Odundo,
- Arnold W. Lambisia,
- Martin Mutunga,
- Salim Mwarumba,
- Lynette Isabella Ochola-Oyier,
- Charles N. Agoti,
- Clement Lewa,
- Elijah Gicheru,
- Jennifer Musyoki,
- Susan Njuguna,
- Horace Gumba,
- Domtila Kimani,
- Jedidah Mwacharo,
- Zaydah R. de Laurent,
- Khadija Said Mohammed,
- Robinson Cheruiyot,
- Donwilliams O. Omuoyo
Affiliations
- Shadrack Mutua
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Brian Bartilol
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Shaban J. Mwangi
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Debra Riako
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Lydia Nyamako
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Bonface M. Gichuki
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Henry Karanja
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Angela Karani
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- John N. Gitonga
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Daisy Mugo
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Brian Tawa
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Wilson Gumbi
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Wesley Cheruiyot
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Metrine Tendwa
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- John K. Nyambu
- Department Of Health Services, Taita-Taveta County Government, Taita-Taveta, Kenya
- Yiakon Sein
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Thani Suleiman Thani
- Department Of Health Services, Mombasa County Government, Mombasa, Kenya
- Shem O. Patta
- Department Of Health Services, Mombasa County Government, Mombasa, Kenya
- Benson Kitole
- Kilifi County Hospital, Kilifi, Kenya
- Eric K. Maitha
- Kilifi County Hospital, Kilifi, Kenya
- Barke S. Muslih
- Hola Referral Hospital, Tana River, Kenya
- Mohamed S. Mwakinangu
- Department Of Health Services, Kwale County Government, Kwale, Kenya
- Philip Bejon
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Benjamin Tsofa
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Joyce U. Nyiro
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- John Ochieng Otieno
- King Fahd Lamu County Referral Hospital, Lamu, Kenya
- Leonard Ndwiga
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Patience Kiyuka
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Johnstone Makale
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Kevin Wamae
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Victor Osoti
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- John Mwita Morobe
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Calleb Odundo
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Arnold W. Lambisia
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Martin Mutunga
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Salim Mwarumba
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Lynette Isabella Ochola-Oyier
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Charles N. Agoti
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Clement Lewa
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Elijah Gicheru
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Jennifer Musyoki
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Susan Njuguna
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Horace Gumba
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Domtila Kimani
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Jedidah Mwacharo
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Zaydah R. de Laurent
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Khadija Said Mohammed
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Robinson Cheruiyot
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Donwilliams O. Omuoyo
- ORCiD
- KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Journal volume & issue
-
Vol. 5
Abstract
Background: The COVID-19 pandemic relies on real-time polymerase chain reaction (qRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), to facilitate roll-out of patient care and infection control measures. There are several qRT-PCR assays with little evidence on their comparability. We report alterations to the developers’ recommendations to sustain the testing capability in a resource-limited setting. Methods: We used a SARS-CoV-2 positive control RNA sample to generate several 10-fold dilution series that were used for optimization and comparison of the performance of the four qRT-PCR assays: i) Charité Berlin primer-probe set, ii) European Virus Archive – GLOBAL (EVAg) primer-probe set, iii) DAAN premixed commercial kit and iv) Beijing Genomics Institute (BGI) premixed commercial kit. We adjusted the manufacturer- and protocol-recommended reaction component volumes for these assays and assessed the impact on cycle threshold (Ct) values. Results: The Berlin and EVAg E gene and RdRp assays reported mean Ct values within range of each other across the different titrations and with less than 5% difference. The DAAN premixed kit produced comparable Ct values across the titrations, while the BGI kit improved in performance following a reduction of the reaction components. Conclusion: We achieved a 2.6-fold and 4-fold increase in the number of tests per kit for the commercial kits and the primer-probe sets, respectively. All the assays had optimal performance when the primers and probes were used at 0.375X, except for the Berlin N gene assay. The DAAN kit was a reliable assay for primary screening of SARS-CoV-2 whereas the BGI kit’s performance was dependent on the volumes and concentrations of both the reaction buffer and enzyme mix. Our recommendation for SARS-CoV-2 diagnostic testing in resource-limited settings is to optimize the assays available to establish the lowest volume and suitable concentration of reagents required to produce valid results.